Fig. 2
From: Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia
DS-5272 inhibits the development of MLL-AF9-driven leukemia in vivo. a Kaplan–Meier survival curves of MLL-AF9 leukemia mice treated with vehicle or DS-5272 from day 3 to day 13. (n = 12 per group). Statistical significance was evaluated by the log rank test. b Representative images and FACS analyses of BM cells derived from vehicle or DS-5272-treated MLL-AF9 leukemia mice (left), and the summarized data for three biologically independent experiments (right). Student t-test. c Frequency of GFP + leukemia cells in peripheral blood (Control: n = 3, DS-5272: n = 4), white blood cell counts (WBC), hemoglobin levels (Hb) and platelet counts (PLT) in leukemic mice treated with vehicle or DS-5272 at day 10. (Vehicle: n = 10, DS-5272: n = 15, data are shown as mean ± s.d.). d (left) Kaplan–Meier survival curves of MLL-AF9 leukemia mice treated with vehicle or DS-5272 from day 11 to day 21. (Control: n = 2, DS-5272: n = 4). Statistical significance was evaluated by the log rank test. (right) FACS plots of peripheral blood cells collected from MLL-AF9 leukemia mice at day 11 and day 21, showing reduction of GFP + leukemia cells at day 21 in the DS-5272-treated mice. e Kaplan–Meier survival curves of mice injected with p53-deficient MLL-AF9 cells, that were treated with vehicle or DS-5272 from day 3 to day 13. (Control: n = 7, DS-5272: n = 6)
